Feed APYX
AP

Apyx Medical Corporation

APYX · NASDAQ

$3.02 +4.86% (+$0.14)
1M -1.31%
Market Cap $127.2M
P/E Ratio -
Div. Yield -
ROE 78.70%

Bulios Fair Price

$1.57

48.0% downside

Current Price

$3.02

Undervalued Fair Value Overvalued

According to Bulios Fair Price, APYX is currently overvalued relative to its market price. How does it work?

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Weak
3/9
Valuation
36 /100
Fair
P/B 11.93x
P/S 2.18x
EV/EBITDA N/A
Growth
38 /100
Stable
Book val. growth 27.13%
Rev. growth 5.89%
FCF growth N/A
Profitability
13 /100
Weak
Net margin 14.78%
Op. margin 6.06%
FCF margin 18.91%
Quality
12 /100
Poor
ROE 78.70%
ROA 14.14%
Asset turnover 0.96x
Debt
23 /100
High
Current ratio 5.68x
Int. coverage -0.43x
Debt/Equity 3.72x
Stability
51 /100
Moderate
Rev. volatility 13.20%
EPS volatility 40.66%
Profitable years 0

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about APYX
Online

About the company

Apyx Medical Corporation (APYX) is a company focused on the development and manufacturing of medical devices and technologies for aesthetic surgery and dermatology. Their main product is the J-Plasma® system, which combines radiofrequency energy with inert argon to create cold plasma for surgical procedures with minimal damage to surrounding tissues. This technology is utilized for various aesthetic procedures, including wrinkle removal, liposuction, skin rejuvenation, and more. Apyx Medical Corporation also focuses on developing and innovating in the field of dermatological and aesthetic medical devices to provide advanced solutions for physicians and their patients. Shares of Apyx Medical Corporation (APYX) could be suitable for investors who are tracking the healthcare sector and seeking investment opportunities in aesthetic surgery and dermatology.

Sector

Healthcare

Industry

Medical - Specialties

CEO

Charles D. Goodwin

Employees

205

Headquarters

Clearwater

Upcoming events

05 NOV

Earnings

Upcoming earnings report

51d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.